Increasing Optionality For Licensors, Rise Of Small-Cap Partners Ongoing
Executive Summary
Companies with market caps below $1bn continue to represent a growing percentage of biopharma deal-making, giving firms looking to license or partner assets increased optionality, Inventiv Health's Neel Patel told a session at BIO 2017.